Skip to main content
S 476 116th Congress Senate

Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Official title: A bill to amend title XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers.

Introduced: February 24, 2020 Introduced by: Wyden, Ron Democratic · Oregon See on congress.gov
Health Government information and archivesHealth care costs and insuranceInflation and pricesMedicarePrescription drugs
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 13, 2019
Read twice and referred to the Committee on Finance.
Feb 13, 2019
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 13, 2019

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019

This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA).

Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies.

As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan.

The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-S-476/
MLA
"S. 476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-476/.
Bluebook (legal)
S. 476, 116th Cong. (2026), https://openamerica.io/bill/116-S-476/.
Markdown link
[S. 476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019](https://openamerica.io/bill/116-S-476/)
Report a problem